Financials
Financial year 2025
Gross margin
€ 0
Profit
Growing€ 65.8 million
▲ 8310% vs 2024
Debts
Low€ 225,036
▲ 25% vs 2024
UCB Ventures from Anderlecht, company number BE0667816096, closed financial year 2025 with a result of € 65.8 million after tax. For that financial year UCB Ventures recorded a gross margin of € 0 and equity of € 213.8 million. Compared with financial year 2024, the result moved from € 782,569 to € 65.8 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 20, 2026.
What happened at UCB Ventures?
What happened at UCB Ventures in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Alistair HENRY stepped down as director. NBB
- Sandrine DUFOUR stepped down as director. NBB
- Jean-Christophe TELLIER stepped down as director. NBB
- Denelle J. WAYNICK JOHNSON stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 65.8 million (▲ 8310% vs 2024). Source: NBB ↗
- Alistair HENRY became a director. NBB
- Denelle J. WAYNICK JOHNSON became a director. NBB
- Sandrine DUFOUR became a director. NBB
In short
From € 6.6 million loss in 2021 to € 65.8 million profit in 2025.
Paid € 2,811 in corporate taxes since 2021.
Best year ever: 2025, with € 65.8 million profit.
Pays suppliers within 85 days on average.
A new publication or filing at UCB Ventures? We notify you, reason included.
Follow UCB VenturesNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
The shares are held by UCB SA (100%) and UCB FIPAR SA (0%). It owns 100% of UCB Ventures Belgium, 25% of Rinri Therapeutics Ltd., 17.5% of Vianautis Bio Limited, 16.5% of Switch Therapeutics Inc., 14.8% of Cenos Therapeutics Inc. and 14.3% of SpliceBio S.L. itself.
Directors
According to the 2025 annual accounts
since 2022 · until 2028
Jean-Christophe TELLIER
Chairman of the board
Also active at: UCB PHARMA, UCB Fipar, UCB Ventures Belgium
since 2022 · until 2028
since 2024 · until 2030
since 2023 · until 2028
Shareholders
100%
0%
Participations
100%
Rinri Therapeutics Ltd.
25%
Vianautis Bio Limited
17.5%
Switch Therapeutics Inc.
16.5%
Cenos Therapeutics Inc.
14.8%
SpliceBio S.L.
14.3%
Iris Medicine Inc
12.3%
StrideBio, inc
11.4%
Walden Biosciences Inc.
11.4%
Locanabio Inc.
6.6%
RTW Biotech Opportunities Ltd
6.1%
AVP Early Stage II SLP
3.2%
Code Biotherapeutics Inc.
2.6%
Neurona Therapeutics Inc.
2.4%
Establishments
Establishment units
Physical locations of this company
Researchdreef 60
1070 Anderlecht
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 10 companies are registered at this address.
UCB Belgium
U C B same network
UCB PHARMA same network
€ 4,622.6 million revenue · 2025
UCB Fipar same network
Fondation Emmanuel Janssen
+5 more
Details
- Company number
- 0667.816.096
- VAT number
- BE 0667.816.096
- Registered office
- Researchdreef 60, 1070 Anderlecht
- Names & denominations
- UCB Ventures
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 19 December 2016
- Peppol
- Not registered
- Activities · NACE
Activiteiten van geldmarkt- en niet-geldmarktbeleggingsfondsen
Beleggingstrusts en -fondsen en vergelijkbare financiële instellingen